Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.
Manuela AlbertelliG RossiE NazzariC GenovaF BielloE RijavecM G Dal BelloL PattiM TagliamentoG BarlettaP MorabitoM BoschettiA DottoD CampanaD FeroneF GrossiPublished in: Journal of endocrinological investigation (2024)
Thyroid function abnormalities are the major irAEs in patients treated with nivolumab, and hypothyroidism onset is associated with prolonged survival. Our findings indicate that the development of hypothyroidism is a positive predictive biomarker of nivolumab antitumor efficacy in patients with NSCLC. Low IGF-I levels could represent a negative prognostic factor during nivolumab therapy.
Keyphrases
- prognostic factors
- advanced non small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- ejection fraction
- chronic kidney disease
- small cell lung cancer
- newly diagnosed
- replacement therapy
- peritoneal dialysis
- oxidative stress
- free survival
- stem cells
- cell proliferation
- mesenchymal stem cells
- smoking cessation
- brain metastases
- cell therapy